Submitted:
09 July 2025
Posted:
10 July 2025
You are already at the latest version
Abstract
Purpura fulminans (PF) is a life-threatening condition characterized by rapidly progressive skin necrosis, often resulting from severe infections or coagulopathy. Since 1995, the management of PF has evolved significantly, driven by advances in medical research, improved diagnostic techniques, and a better understanding of the underlying pathophysiology. This historical reflection examines the key developments in PF management over the past three decades, highlighting the shift from conventional therapeutic approaches to more targeted interventions. Early strategies primarily focused on aggressive supportive care and the use of broad-spectrum antibiotics. However, recent innovations have introduced specific therapies, including the use of anticoagulants and immunomodulatory agents, which address the coagulopathic component of the disease more effectively. Additionally, the role of multidisciplinary teams in managing PF has gained prominence, emphasizing the importance of collaborative care in improving patient outcomes. This review underscores the necessity for ongoing research and the integration of emerging technologies in the management of PF, aiming to enhance clinical practices and reduce morbidity and mortality associated with this severe condition. The evolution of PF management serves as a compelling case study in the broader context of critical care medicine, highlighting the importance of adapting treatment protocols to reflect new scientific insights and clinical experiences.
Keywords:
purpura fulminans
; sepsis
; pseudomonas sepsis
Chapter 1: Introduction to Purpura Fulminans
1.1. Background
Purpura fulminans (PF) is a critical condition characterized by the rapid onset of skin necrosis and systemic coagulopathy, often leading to severe morbidity and mortality. It is most frequently associated with infections, particularly those caused by Neisseria meningitidis and Streptococcus pneumoniae, but can also occur in the context of other medical conditions such as disseminated intravascular coagulation (DIC) and severe sepsis. The clinical manifestation of PF is marked by the appearance of purpuric lesions, which evolve into extensive necrosis, necessitating urgent medical intervention. Given its acute nature and potential for rapid deterioration, understanding the management of PF is crucial for healthcare providers in critical care and emergency medicine.
1.2. Historical Perspective
Since the mid-1990s, significant advancements in the understanding and management of PF have emerged. Prior to this period, treatment protocols were largely non-specific, focusing on supportive care and broad-spectrum antibiotics. The lack of targeted therapeutic options reflected a limited understanding of the underlying pathophysiological mechanisms driving the condition.
The late 1990s and early 2000s witnessed a paradigm shift as research began to elucidate the complex interplay between coagulopathy, inflammation, and vascular dysfunction in PF. This evolving comprehension paved the way for more sophisticated management strategies that included not only aggressive supportive measures but also the introduction of anticoagulant therapy and immunomodulatory agents. Such developments underscored the necessity for a multifaceted approach, combining insights from hematology, infectious disease, and critical care.
1.3. Significance of the Study
This chapter aims to provide a comprehensive overview of the evolution of PF management since 1995, highlighting key milestones in clinical practice and research. By examining historical trends, this reflection seeks to illuminate the progress made in the diagnosis, treatment, and overall understanding of PF. Furthermore, it emphasizes the importance of adapting clinical guidelines to incorporate new evidence and innovative therapeutic modalities, ultimately improving patient outcomes.
The significance of this study extends beyond the realm of PF; it serves as a case study in the broader context of critical care medicine. The evolution of management strategies reflects the dynamic nature of medical knowledge and the necessity for continuous learning and adaptation in clinical practice. As such, this chapter sets the stage for subsequent discussions on specific treatment modalities, interdisciplinary collaboration, and future directions in PF management.
1.4. Objectives
The primary objectives of this chapter are as follows:
- To outline the historical context of purpura fulminans management from 1995 to the present.
- To identify key advancements in therapeutic strategies and diagnostic techniques.
- To analyze the impact of multidisciplinary care on patient outcomes.
- To discuss future directions for research and clinical practice in the management of PF.
Through this exploration, we aim to provide a foundational understanding of PF and its management, setting the groundwork for a detailed examination of therapeutic advancements and ongoing challenges in subsequent chapters.
Chapter 1: Introduction to Purpura Fulminans
1.1. Background
Purpura fulminans (PF) is a critical and often devastating condition characterized by the rapid onset of purpuric skin lesions, accompanied by systemic coagulopathy and, in many cases, multi-organ dysfunction. This acute disorder primarily results from severe infections, particularly those caused by Neisseria meningitidis, Streptococcus pneumoniae, and other pathogens. The clinical picture of PF is marked by the emergence of hemorrhagic necrosis, which can lead to significant morbidity and mortality if not promptly addressed. Historically, PF has posed significant challenges for clinicians, necessitating swift diagnosis and aggressive management.
The pathophysiology of PF is complex, involving a synergistic interplay between coagulation abnormalities, inflammatory responses, and vascular injury. In severe cases, the condition can lead to disseminated intravascular coagulation (DIC), where an overwhelming inflammatory response triggers widespread clotting and subsequent bleeding. Understanding these mechanisms is crucial for developing effective therapeutic strategies.
1.2. Historical Perspective
1.2.1. Pre-1995 Management Approaches
Before 1995, the management of PF was largely rudimentary. Treatment protocols focused on supportive care, including fluid resuscitation, oxygenation, and broad-spectrum antibiotics aimed at addressing the underlying infections. The lack of targeted therapies reflected an insufficient understanding of the condition's pathophysiology. Clinicians primarily relied on empirical approaches, often with limited success.
Complications such as limb ischemia and organ failure were common, and the prognosis remained poor for many patients. The absence of established guidelines and the variability in clinical practice contributed to discrepancies in outcomes, highlighting the urgent need for a more systematic approach to PF management.
1.2.2. Advancements in Understanding (1995-2005)
The mid to late 1990s marked a significant turning point in the management of PF. A growing body of research began to elucidate the underlying mechanisms of the disease, particularly the role of coagulopathy and inflammation in its progression. Studies during this period highlighted the importance of early recognition and intervention, emphasizing the need for a multidisciplinary approach to care.
The introduction of more sophisticated diagnostic tools, such as coagulation studies and imaging techniques, allowed for earlier identification of PF and its complications. This period also saw the emergence of case studies and clinical trials that began to establish the efficacy of specific treatment modalities. For example, the use of activated protein C was investigated as a potential therapeutic agent for addressing coagulopathy in severe sepsis, although its role in PF was yet to be fully defined.
1.2.3. The Evolution of Management Strategies (2005-2015)
From 2005 onward, the management of PF continued to evolve significantly. The introduction of targeted therapies marked a paradigm shift in clinical practice. The recognition of the coagulopathic nature of PF led to the exploration of anticoagulants as a means to mitigate the thrombotic complications associated with the condition. Trials began to reveal the potential benefits of agents such as unfractionated heparin and low molecular weight heparin in improving outcomes for patients with PF.
Additionally, immunomodulatory therapies gained traction as researchers sought to address the inflammatory component of PF. Corticosteroids and other agents aimed at modulating the immune response were increasingly utilized, although their efficacy remained a topic of debate. The integration of these therapies into clinical practice underscored the importance of a holistic approach to PF management that considered both the infectious and non-infectious components of the disease.
1.2.4. Recent Developments and Current Practices (2015-Present)
In recent years, the management of PF has continued to advance, guided by ongoing research and clinical innovation. The establishment of clinical guidelines and protocols has become increasingly important in standardizing care and improving patient outcomes. Multidisciplinary teams, including intensivists, infectious disease specialists, hematologists, and surgeons, have become integral to the management of PF, ensuring a comprehensive approach to treatment.
Recent studies have explored the role of novel therapies, such as monoclonal antibodies and other biologics, which target specific pathways involved in coagulation and inflammation. The use of advanced imaging techniques has also improved the ability to assess vascular compromise and guide surgical interventions when necessary. These developments reflect a growing recognition of the complexity of PF and the necessity for tailored treatment strategies.
1.3. Significance of the Study
This historical reflection on the evolution of PF management since 1995 is significant for several reasons. Firstly, it underscores the progress made in understanding the pathophysiology of PF and the development of targeted therapeutic interventions. By documenting key advancements, this study highlights the importance of integrating evidence-based practices into clinical care.
Moreover, the evolution of PF management serves as a case study in the broader context of critical care medicine. It illustrates the dynamic nature of medical knowledge and the necessity for continuous adaptation in clinical practice. As new research emerges, healthcare providers must remain vigilant in updating their protocols and treatment modalities to reflect the latest evidence.
1.4. Objectives
The primary objectives of this chapter are as follows:
- Outline the historical context of purpura fulminans management from 1995 to the present: By examining the developments in PF management, we aim to provide a comprehensive overview of the advancements made over the past three decades.
- Identify key advancements in therapeutic strategies and diagnostic techniques: This chapter will highlight significant milestones in the evolution of treatment modalities, including the introduction of anticoagulants and immunomodulatory therapies.
- Analyze the impact of multidisciplinary care on patient outcomes: The importance of collaborative approaches in managing PF will be emphasized, showcasing the benefits of integrated care.
- Discuss future directions for research and clinical practice in the management of PF: Identifying gaps in current knowledge and potential areas for further investigation will provide a roadmap for future advancements.
Through this exploration, we aim to contribute to the understanding of PF and its management, setting the groundwork for a detailed examination of therapeutic advancements and ongoing challenges in subsequent chapters. The evolution of PF management reflects not only scientific progress but also the enduring commitment of the medical community to improve patient care and outcomes in the face of complex and life-threatening conditions.
Chapter 2: Pathophysiology of Purpura Fulminans
2.1. Introduction
Understanding the pathophysiology of purpura fulminans (PF) is crucial for developing effective management strategies. PF is characterized by the rapid onset of purpuric lesions, often resulting from a cascade of events initiated by severe infection, coagulopathy, and systemic inflammation. This chapter delves into the complex biological mechanisms underlying PF, tracing its pathogenesis and highlighting how these insights have informed the evolution of management strategies since 1995.
2.2. The Role of Infection
2.2.1. Infectious Agents
PF is frequently associated with infections caused by specific pathogens, most notably Neisseria meningitidis and Streptococcus pneumoniae. These organisms can lead to severe sepsis, triggering a systemic inflammatory response that is pivotal in the development of PF. The virulence of these pathogens is often linked to their ability to evade the host immune response, leading to increased bacterial load and subsequent tissue damage.
For example, N. meningitidis can penetrate the vascular endothelium, causing direct damage and promoting coagulopathy. Similarly, S. pneumoniae can induce inflammatory cytokines that exacerbate the host's immune response, further contributing to vascular compromise and necrosis.
2.2.2. Mechanisms of Vascular Injury
The vascular injury seen in PF is a critical component of its pathophysiology. Infection leads to the activation of endothelial cells, which express adhesion molecules that facilitate the recruitment of inflammatory cells. This process is associated with increased vascular permeability, allowing plasma proteins and leukocytes to migrate into surrounding tissues, resulting in edema and ultimately, tissue necrosis.
The formation of microthrombi is another key mechanism. Inflammatory mediators stimulate the coagulation cascade, leading to the activation of platelets and the deposition of fibrin within the microvasculature. This microvascular thrombosis can severely restrict blood flow, further exacerbating ischemia and contributing to the formation of purpuric lesions.
2.3. Coagulation and Hemostasis
2.3.1. Coagulation Cascade Activation
The coagulation cascade plays a central role in the pathophysiology of PF. In response to infection and inflammation, the intrinsic and extrinsic pathways of coagulation are activated, leading to the formation of thrombin and fibrin. This process is essential for hemostasis but can become dysregulated in the context of severe infections.
In PF, excessive thrombin generation leads to a state of hypercoagulability, which is often coupled with thrombocytopenia and a consumptive coagulopathy known as disseminated intravascular coagulation (DIC). The interplay between coagulation and inflammation creates a vicious cycle, where microvascular thrombosis and tissue injury further promote the inflammatory response.
2.3.2. Role of Anticoagulants
Given the critical role of coagulation in PF, the use of anticoagulants has emerged as a therapeutic strategy. Early studies indicated that agents like unfractionated heparin could prevent thrombus formation and improve microcirculation, potentially mitigating the severity of PF. The understanding of how anticoagulants can modulate the coagulation cascade has informed treatment protocols, leading to their increased utilization in clinical practice.
2.4. Inflammatory Response
2.4.1. Cytokine Storm
The inflammatory response in PF is characterized by the release of pro-inflammatory cytokines, often referred to as a "cytokine storm." Cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) are released in response to infection and contribute to systemic inflammation. This heightened inflammatory state can lead to widespread endothelial dysfunction and vascular permeability.
The cytokine storm not only promotes coagulopathy but also exacerbates tissue injury. As inflammatory mediators accumulate, they amplify the immune response, leading to further endothelial activation and increased leukocyte recruitment, resulting in a cycle of inflammation and damage.
2.4.2. Immune Dysregulation
In some cases, the host immune response may become dysregulated, contributing to the pathophysiology of PF. This dysregulation can manifest as an inadequate response to infection or, conversely, an overwhelming inflammatory response that exacerbates tissue injury. Understanding the balance between effective immune activation and excessive inflammation is crucial for developing targeted therapies.
2.5. Clinical Implications
2.5.1. Diagnostic Considerations
A thorough understanding of the pathophysiology of PF has significant implications for diagnosis. Clinicians must be vigilant in recognizing the early signs of PF, particularly in patients presenting with severe infections. Diagnostic tools, including coagulation studies and imaging, play a pivotal role in identifying the condition and its complications.
2.5.2. Therapeutic Strategies
Insights into the pathophysiology of PF have informed the evolution of management strategies. The recognition of the importance of both coagulation and inflammation has led to the development of targeted therapies, including anticoagulants and immunomodulatory agents. Clinical guidelines now emphasize a multidisciplinary approach that integrates insights from various specialties to optimize patient care.
2.6. Conclusion
The pathophysiology of purpura fulminans is characterized by a complex interplay of infection, coagulation, and inflammation. Understanding these mechanisms is essential for developing effective management strategies and improving patient outcomes. Since 1995, advancements in our understanding of PF have led to significant changes in clinical practice, emphasizing the importance of early recognition, targeted therapies, and multidisciplinary care. As research continues to evolve, further insights into the pathophysiology of PF will likely yield new therapeutic options and improve the prognosis for affected patients. This chapter serves as a foundation for exploring the historical evolution of PF management and the ongoing challenges that clinicians face in treating this life-threatening condition.
Chapter 5: Future Directions in Purpura Fulminans Management
5.1. Introduction
As the understanding of purpura fulminans (PF) continues to evolve, so too does the landscape of its management. The advancements made since 1995 have significantly improved patient outcomes; however, challenges remain. This chapter discusses the future directions in PF management, focusing on emerging therapies, advancements in diagnostics, the role of precision medicine, and the necessity of ongoing research. By examining these areas, we aim to outline a roadmap for enhancing the care of patients afflicted by this complex and life-threatening condition.
5.2. Emerging Therapies
5.2.1. Novel Anticoagulants
The use of anticoagulants has been a pivotal aspect of PF management, particularly in addressing the hypercoagulable state associated with the condition. While traditional anticoagulants such as unfractionated heparin and low molecular weight heparin have shown efficacy, the development of novel anticoagulants presents new opportunities for improved management. Direct oral anticoagulants (DOACs) offer advantages such as oral administration and predictable pharmacokinetics, potentially simplifying treatment regimens. Ongoing studies are necessary to establish the safety and efficacy of these agents in the context of PF.
5.2.2. Targeted Biologics
Biologic therapies targeting specific inflammatory pathways have emerged as promising options in managing PF. Agents that inhibit pro-inflammatory cytokines, such as TNF-α and IL-6, are being investigated for their potential to mitigate the cytokine storm characteristic of PF. Early clinical trials suggest that these agents may reduce inflammation and improve outcomes in critically ill patients. Further research is required to identify the most suitable patient populations for these therapies and to determine their long-term effects.
5.2.3. Immunotherapy
The role of immunotherapy in managing PF is an exciting area of exploration. Approaches such as monoclonal antibodies that target specific pathogens or modulate the immune response could enhance the body’s ability to combat infections while minimizing collateral damage to host tissues. Research into the immunological aspects of PF could lead to innovative treatment modalities that not only address the acute phase of the disease but also provide long-term benefits by enhancing immune resilience.
5.3. Advancements in Diagnostics
5.3.1. Rapid Diagnostic Techniques
The timely identification of infectious agents is critical in the management of PF. Advances in rapid diagnostic techniques, including polymerase chain reaction (PCR) assays and next-generation sequencing, enable quicker and more accurate identification of pathogens. These technologies can facilitate early initiation of targeted therapy, potentially improving outcomes. Ongoing investment in diagnostic innovation will be crucial for enhancing the speed and accuracy of PF diagnosis.
5.3.2. Biomarkers for Prognosis
The identification of biomarkers associated with PF could revolutionize management strategies. Biomarkers that predict disease severity, response to treatment, or the likelihood of complications could allow for more personalized approaches. Research efforts aimed at discovering such biomarkers will be essential in guiding treatment decisions and improving prognostic accuracy.
5.4. Precision Medicine
The concept of precision medicine—tailoring treatments based on individual patient characteristics—holds significant promise for PF management. Advances in genomics and proteomics can provide insights into individual responses to therapy, allowing clinicians to customize treatment protocols. For example, genetic profiles may elucidate predispositions to severe inflammatory responses or coagulopathy, informing the choice of anticoagulants or immunomodulatory therapies.
5.4.1. Risk Stratification
Implementing precision medicine approaches will enable better risk stratification among patients with PF. By identifying high-risk patients, healthcare providers can initiate more aggressive interventions early in the disease course, potentially altering the trajectory of the illness. This tailored approach could minimize complications and improve overall outcomes.
5.5. The Role of Multidisciplinary Teams
As PF management becomes increasingly complex, the role of multidisciplinary teams will continue to grow. Collaboration among specialists from critical care, infectious diseases, hematology, and other fields is essential for optimizing patient care. The integration of diverse expertise allows for comprehensive assessments and individualized treatment plans, addressing the multifaceted nature of PF.
5.5.1. Education and Training
Ongoing education and training for healthcare providers will be crucial in adapting to evolving management strategies. Ensuring that clinicians are aware of the latest research findings and treatment modalities will enhance the quality of care provided to patients with PF. Collaborative training programs that emphasize the importance of interdisciplinary communication and teamwork can further strengthen the management of this complex condition.
5.6. Research and Clinical Trials
5.6.1. Continued Exploration of Pathophysiology
Ongoing research into the pathophysiology of PF is essential for identifying novel therapeutic targets. Understanding the molecular mechanisms underlying coagulopathy and inflammation will inform the development of targeted interventions. Collaborative efforts among researchers, clinicians, and institutions will be vital in advancing our knowledge and translating findings into clinical practice.
5.6.2. Importance of Clinical Trials
Clinical trials remain the cornerstone of evidence-based medicine. As new therapies and diagnostic approaches emerge, rigorous clinical trials will be necessary to establish their safety and efficacy in PF management. Engaging patients in clinical research not only provides them with access to cutting-edge therapies but also contributes to the broader understanding of PF and its treatment.
5.7. Conclusion
The future of purpura fulminans management is poised for significant advancements, driven by emerging therapies, innovative diagnostics, and the principles of precision medicine. As our understanding of the condition continues to deepen, the integration of multidisciplinary care and ongoing research will be crucial in optimizing patient outcomes. By embracing these future directions, the medical community can enhance the management of PF, ultimately improving the prognosis for patients affected by this life-threatening condition. This chapter underscores the importance of adaptability and collaboration in navigating the evolving landscape of PF management, ensuring that care remains aligned with the latest scientific insights and clinical practices.
Chapter 6: Future Directions in the Management of Purpura Fulminans
6.1. Introduction
The management of purpura fulminans (PF) has undergone substantial transformation since 1995, marked by a deeper understanding of its pathophysiology and the emergence of targeted therapies. However, as we look to the future, several challenges and opportunities remain in optimizing the management of this complex condition. This chapter explores potential future directions in PF management, focusing on advancements in research, novel therapeutic strategies, the importance of personalized medicine, and the integration of technology in clinical practice.
6.2. Research Opportunities
6.2.1. Understanding Pathophysiological Mechanisms
Ongoing research is essential to further elucidate the pathophysiological mechanisms underlying PF. While significant progress has been made, gaps remain in our understanding of the interplay between infection, coagulation, and inflammation. Future research should focus on identifying specific biomarkers that correlate with disease severity and treatment response, enabling clinicians to stratify patients based on risk and tailor interventions accordingly.
6.2.2. Clinical Trials for Novel Therapies
The exploration of novel therapeutic agents represents a promising avenue for improving PF management. Clinical trials assessing the efficacy of biologic agents, such as monoclonal antibodies targeting specific inflammatory pathways, could provide valuable insights into more effective treatment options. Additionally, research into adjunctive therapies, such as anticoagulants with improved safety profiles or novel immunomodulatory agents, is crucial for refining treatment protocols.
6.2.3. Longitudinal Studies on Outcomes
Longitudinal studies assessing the long-term outcomes of PF survivors are vital for understanding the full impact of the condition. These studies can provide insights into the quality of life, psychological sequelae, and long-term complications faced by patients post-recovery. Understanding these aspects can inform the development of comprehensive care plans that address both immediate and long-term needs.
6.3. Novel Therapeutic Strategies
6.3.1. Targeted Anticoagulation
As our understanding of the coagulation cascade improves, the development of targeted anticoagulant therapies could enhance the safety and efficacy of PF management. Agents that selectively inhibit specific pathways within the coagulation cascade may reduce the risk of bleeding while still effectively mitigating thrombotic complications. Research into these agents should be prioritized, as they could revolutionize the management of PF and similar coagulopathic conditions.
6.3.2. Immunomodulatory Therapies
The exploration of advanced immunomodulatory therapies presents another opportunity for innovation in PF management. Therapies that specifically modulate the inflammatory response, rather than broadly suppressing it, may lead to improved patient outcomes. The development of agents that can fine-tune the immune response without compromising the host's ability to fight infection is a promising area for future investigation.
6.3.3. Combination Therapies
Combination therapies that address multiple facets of PF—such as infection, coagulation, and inflammation—may offer synergistic benefits. Future studies should explore the potential of combining anticoagulants with immunomodulatory agents, as well as the integration of antibiotics with agents that enhance vascular integrity. Such approaches could optimize treatment outcomes and reduce the incidence of complications.
6.4. Personalized Medicine
6.4.1. Tailoring Treatment Based on Genetic and Biomarker Profiles
The future of PF management may increasingly rely on personalized medicine, where treatment approaches are tailored to individual patient profiles. Advances in genetics and biomarker research could enable clinicians to predict responses to specific therapies, allowing for more effective treatment strategies. By identifying genetic predispositions to severe inflammatory responses or coagulopathy, healthcare providers can better tailor interventions to meet individual patient needs.
6.4.2. Implementing Precision Medicine in Clinical Practice
Integrating precision medicine into clinical practice requires the development of guidelines that incorporate genetic and biomarker information into decision-making processes. Educational initiatives for healthcare providers will be essential to ensure that clinicians are equipped to utilize these advancements effectively. Collaborative efforts between researchers, clinicians, and policymakers will be necessary to facilitate the adoption of personalized approaches in PF management.
6.5. Technological Integration
6.5.1. Advancements in Diagnostic Tools
The integration of advanced diagnostic tools, such as point-of-care testing and rapid genomic sequencing, has the potential to revolutionize PF management. These technologies can enable early detection of pathogens and rapid assessment of coagulation status, facilitating timely interventions. Future developments in diagnostic technology should focus on enhancing accuracy, speed, and accessibility to improve patient outcomes.
6.5.2. Telemedicine and Remote Monitoring
Telemedicine has emerged as a valuable tool in managing various health conditions, and its application in PF management could enhance patient care. Remote monitoring of patients, particularly those at high risk for complications, allows for timely interventions and reduces the need for frequent hospital visits. Future research should explore the effectiveness of telemedicine in improving outcomes for PF patients, particularly in rural or underserved areas where access to specialized care may be limited.
6.5.3. Data Analytics and Artificial Intelligence
The application of data analytics and artificial intelligence (AI) in the management of PF presents exciting opportunities for improving clinical decision-making. AI algorithms can analyze vast amounts of data to identify patterns and predict patient outcomes, enabling more accurate risk stratification and personalized treatment plans. Future studies should investigate the feasibility and efficacy of integrating AI into clinical workflows to enhance PF management.
6.6. Conclusion
The future of purpura fulminans management is poised for significant advancements, driven by ongoing research, novel therapeutic strategies, personalized medicine, and technological integration. As we continue to deepen our understanding of the condition's pathophysiology and explore innovative treatment options, the potential to improve patient outcomes becomes increasingly attainable. A collaborative approach that involves researchers, clinicians, and policymakers will be essential in translating these advancements into clinical practice. By embracing these future directions, we can ensure that the management of PF evolves in alignment with emerging evidence, ultimately improving the prognosis for patients affected by this life-threatening condition.
References
- Krishnan, S.; Shah, K.; Dhillon, G.; Presberg, K. 1995: FATAL PURPURA FULMINANS AND FULMINANT PSEUDOMONAL SEPSIS. Critical Care Medicine 2016, 44(12), 574. [Google Scholar] [CrossRef]
- Warner, P. M.; Kagan, R. J.; Yakuboff, K. P.; Kemalyan, N.; Palmieri, T. L.; Greenhalgh, D. G.; Warden, G. D. Current management of purpura fulminans: a multicenter study. The Journal of burn care & rehabilitation 2003, 24(3), 119–126. [Google Scholar]
- Nolan, J.; Sinclair, R. Review of management of purpura fulminans and two case reports. British Journal of Anaesthesia 2001, 86(4), 581–586. [Google Scholar] [CrossRef] [PubMed]
- Chalmers, E.; Cooper, P.; Forman, K.; Grimley, C.; Khair, K.; Minford, A.; Mumford, A. D. Purpura fulminans: recognition, diagnosis and management. Archives of disease in childhood 2011, 96(11), 1066–1071. [Google Scholar] [CrossRef]
- Edlich, R.; Cross, C. L.; Dahlstrom, J. J.; Long, W. B., III. Modern concepts of the diagnosis and treatment of purpura fulminans. Journal of Environmental Pathology, Toxicology and Oncology 2008, 27(3). [Google Scholar] [CrossRef]
- Price, V.; Ledingham, D. L.; Krümpel, A.; Chan, A. K. Diagnosis and management of neonatal purpura fulminans. In Seminars in Fetal and Neonatal Medicine; WB Saunders, December 2011; Vol. 16, No. 6, pp. 318–322. [Google Scholar]
- Talwar, A.; Kumar, S.; Gopal, M. G.; Nandini, A. S. Spectrum of purpura fulminans: report of three classical prototypes and review of management strategies. Indian Journal of Dermatology, Venereology and Leprology 2012, 78, 228. [Google Scholar] [CrossRef] [PubMed]
- Klifto, K. M.; Gurno, C. F.; Grzelak, M. J.; Seal, S. M.; Asif, M.; Hultman, C. S.; Caffrey, J. A. Surgical outcomes in adults with purpura fulminans: a systematic review and patient-level meta-synthesis. Burns & Trauma 2019, 7. [Google Scholar]
- Betrosian, A. P.; Berlet, T.; Agarwal, B. Purpura fulminans in sepsis. The American journal of the medical sciences 2006, 332(6), 339–345. [Google Scholar] [CrossRef]
- Dudgeon, D. L.; Kellogg, D. R.; Gilchrist, G. S.; Woolley, M. M. Purpura fulminans. Archives of Surgery 1971, 103(3), 351–358. [Google Scholar] [CrossRef]
- Childers, B. J.; Cobanov, B. Acute infectious purpura fulminans: a 15-year retrospective review of 28 consecutive cases. The American Surgeon 2003, 69(1), 86–90. [Google Scholar] [CrossRef]
- Davis, M. D.; Dy, K. M.; Nelson, S. Presentation and outcome of purpura fulminans associated with peripheral gangrene in 12 patients at Mayo Clinic. Journal of the American Academy of Dermatology 2007, 57(6), 944–956. [Google Scholar] [CrossRef]
- Schneiderman, P. The vascular purpuras. Williams Hematology 1995, 5, 1401–08. [Google Scholar]
- Hassan, Z.; Mullins, R. F.; Friedman, B. C.; Shaver, J. R.; Alam, B.; Mian, M. A. Purpura fulminans: a case series managed at a regional burn center. Journal of burn care & research 2008, 29(2), 411–415. [Google Scholar]
- Kravitz, G. R.; Dries, D. J.; Peterson, M. L.; Schlievert, P. M. Purpura fulminans due to Staphylococcus aureus. Clinical Infectious Diseases 2005, 40(7), 941–947. [Google Scholar] [CrossRef] [PubMed]
- Brozyna, J. R.; Sardiña, L. A.; Sharma, A.; Theil, K. S.; Bergfeld, W. F. Acute purpura fulminans—a rare cause of skin necrosis: A single-institution clinicopathological experience. Journal of Cutaneous Pathology 2020, 47(11), 1003–1009. [Google Scholar] [CrossRef] [PubMed]
- Sheridan, R. L.; Briggs, S. E.; Remensnyder, J. P.; Tompkins, R. G. Management strategy in purpura fulminans with multiple organ failure in children. Burns 1996, 22(1), 53–56. [Google Scholar] [CrossRef] [PubMed]
- Faust, S. N.; Nadel, S. Purpura fulminans. Life-threatening dermatoses and emergencies in dermatology 2009, 45–55. [Google Scholar]
- Morris, M. E.; Maijub, J. G.; Walker, S. K.; Gardner, G. P.; Jones, R. G. Meningococcal sepsis and purpura fulminans: the surgical perspective. Postgraduate Medical Journal 2013, 89(1052), 340–345. [Google Scholar] [CrossRef]
- Chu, D. Z.; Blaisdell, F. W. Purpura fulminans. The American Journal of Surgery 1982, 143(3), 356–362. [Google Scholar] [CrossRef]
- Contou, D.; Canoui-Poitrine, F.; Coudroy, R.; Préau, S.; Cour, M.; Barbier, F.; De Prost, N. Long-term quality of life in adult patients surviving purpura fulminans: an exposed-unexposed multicenter cohort study. Clinical Infectious Diseases 2019, 69(2), 332–340. [Google Scholar] [CrossRef]
- Jones, E.; Stair-Buchmann, M.; Kotliar, S.; Haith, L. Purpura fulminans in toxic epidermal necrolysis: case report and review. Journal of Burn Care & Research 2015, 36(6), e274–e282. [Google Scholar]
- Katoch, S.; Kallappa, R.; Shamanur, M. B.; Gandhi, S. Purpura fulminans secondary to rickettsial infections: a case series. Indian dermatology online journal 2016, 7(1), 24–28. [Google Scholar] [PubMed]
- Macheret, F.; Pundi, K. N.; Broomall, E. M.; Davis, D. M.; Rodriguez, V.; Brands, C. K. Empiric treatment of protracted idiopathic purpura fulminans in an infant: a case report and review of the literature. Journal of medical case reports 2011, 5, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Theron, A.; Dautremay, O.; Boissier, E.; Zerroukhi, A.; Baleine, J.; Moulis, L.; Biron-Andreani, C. Idiopathic purpura fulminans associated with anti-protein S antibodies in children: a multicenter case series and systematic review. Blood advances 2022, 6(2), 495–502. [Google Scholar] [CrossRef]
- Manco-Johnson, M. J.; Bomgaars, L.; Palascak, J.; Shapiro, A.; Geil, J.; Fritsch, S.; Gelmont, D. Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency. Thrombosis and Haemostasis 2016, 116(07), 58–68. [Google Scholar] [CrossRef]
- De Cloedt, L.; Vanholder, I.; Arkaz, C.; Lafaire, C.; Thiessen, F.; Tondu, T.; Duval, E. L. From purpura to idiopathic purpura fulminans: a guidance in diagnosis and therapy, 2023.
- Vincent, J. L.; Nadel, S.; Kutsogiannis, D. J.; Gibney, R. N.; Yan, S. B.; Wyss, V. L.; Janes, J. M. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies. Critical Care 2005, 9, 1–13. [Google Scholar] [CrossRef]
- Manco-Johnson, M. J.; Nuss, R.; Key, N.; Moertel, C.; Jacobson, L.; Meech, S.; Lefkowitz, J. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. The Journal of pediatrics 1996, 128(3), 319–323. [Google Scholar] [CrossRef]
- Carpenter, C. T.; Kaiser, A. B. Purpura fulminans in pneumococcal sepsis: case report and review. Scandinavian journal of infectious diseases 1997, 29(5), 479–483. [Google Scholar] [CrossRef]
- Warkentin, T. E. Limb ischemic necrosis secondary to microvascular thrombosis: a brief historical review. In Seminars in thrombosis and hemostasis; Thieme Medical Publishers, Inc, July 2024; Vol. 50, No. 05, pp. 760–772. [Google Scholar]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
